IRWD — Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals (IRWD) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $106.5 million for Q1 2026.
• GAAP Net Income: $40.8 million.
• Adjusted EBITDA: $76.7 million.
• LINZESS Net Sales: $272.5 million, representing a 97% year-over-year increase, driven by improved net pricing and 5% prescription demand growth.
• Cash Position: $220.5 million in cash and cash equivalents, with $105.8 million in accounts receivable expected to be collected before the June 15 convertible note maturity.

2. Strategic Updates and Business Highlights

• LINZESS: Continues to lead in the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation. The FDA accepted a supplemental NDA for LINZESS for children aged 2 to 5, with a PDUFA date of May 24, 2026.
• Apraglutide: Progressing in the STARS-2 Phase III trial for short bowel syndrome with intestinal failure (SBS-IF). The trial is set to initiate in Q2 2026, following successful site feasibility assessments.
• Commercial Collaboration: U.S. brand collaboration revenue increased by 169% to $104.2 million compared to Q1 2025.

3. Forward Guidance and Outlook

• 2026 Guidance:
  • LINZESS U.S. net sales expected between $1.125 billion and $1.175 billion.
  • Ironwood revenues projected between $450 million and $475 million.
  • Adjusted EBITDA anticipated to exceed $300 million.
• The company expects more consistent quarterly net sales for LINZESS throughout 2026, mitigating the fluctuations seen in 2025.

4. Bad News, Challenges, or Points of Concern

• Prescription Demand Growth: While Q1 showed a 5% increase, the company anticipates a slowdown in growth for the remainder of 2026, particularly in Medicaid, which could impact overall demand.
• Market Penetration for Apraglutide: Current estimates suggest only 1,500 to 2,000 of the 8,000 potential SBS-IF patients are on existing GLP-2 therapies, indicating a significant opportunity but also highlighting the challenge of market penetration.
• Reimbursement Changes: AbbVie's reimbursement for Ironwood's commercial expenses decreased by 90% compared to the previous year, suggesting potential financial strain.

5. Notable Q&A Insights

• LINZESS Demand: Management expressed confidence in the Q1 results being in line with expectations, with no significant one-time items affecting guidance.
• Apraglutide Market Potential: There is substantial opportunity for increasing GLP-2 utilization, with management indicating that the market for SBS-IF patients is underpenetrated.
• Life Cycle Management: Discussions around potential OTC availability for LINZESS are ongoing, with plans to update stakeholders as more information becomes available.
• Operational Execution for STARS-2: Management is leveraging learnings from the previous STARS trial to ensure efficient site initiation and patient recruitment for the upcoming trial.

Overall, Ironwood Pharmaceuticals demonstrated strong financial performance in Q1 2026, with promising developments for LINZESS and apraglutide, while also acknowledging potential challenges in demand growth and market penetration.